Immunoinformatics Study on Early 4 Protein of Human Papillomavirus Type 16 for Cervical Cancer Vaccine Peptide Candidate
DOI:
https://doi.org/10.15575/biodjati.v4i2.5414Keywords:
cervical cancer, Early 4, Human papillomavirus, immunoinformatics, vaccineAbstract
 The aims of this study were to carry out testing of the early 4 protein of type 16 HPV through immunoinformatics meth-ods in an effort to get the peptide vaccine candidate for cervical cancer. The software used are IEDB-AR, CABSdock and Accelrys Discovery Study 4.5. Based on the analysis that sequence of ami-no acid lysine, leucine, leucine, glycine, serine, threonine, tryp-tophan, proline and threonine (KLLGSTWPT) and the sequence of amino acid tyrosine, tyrosine, valine, leucine, histidine, leucine, cysteine, leucine, alanine, alanine, threonine, lysine, tyrosine, pro-line and leucine (YYVLHLCLAATKYPL) are peptide vaccine can-didate for cervical cancer from the early 4 protein of HPV type 16Â
References
Bellone M. (2005). Autoimmune Disease: Pathogenesis. Italy: John Wiley & Sons (http://www.els.net).
Blaszczyk, M., Mateusz, K., Maksim, K., Lukasz, W., Aleksander, D. & Andrzej K. (2016). Modeling of Protein-Pep-tide Interactions Using The CABS-dock Web Server for Binding Site Search and Flexible Docking. Method. 93, 72-83.
Bruni, L., Albero, G., Serrano, B., Mena, M., Gómez, D., Muñoz, J., Bosch, FX. & de Sanjosé, S. (2019). ICO/IARC Informa
tion Centre on HPV and Cancer (HPV Information Centre). Summary Report. Human Papillomavirus and Related Diseases in Indonesia.
Fatima, S. S. & Desu, J. (2014). Proteome Analysis and Antigenic Peptide Predic-tion of Beta Corona Cirus, A Cause of MERS. Helix, (5), 590-583.
Fleri, W. (2012). T-Cell epitopes - MHC Class I Binding Prediction Tools Description. Retrieved from http://help.iedb.org/ entries/21903572-t-cell-epitopes-mhc-class-ii-binding-prediction-tools-de-scription.
Fleri, W. (2012). T-Cell epitopes - MHC Class II Binding Prediction Tools Description IEDB Solutions Center. Retrieved from http://help.iedb.org/entries/21903572-t-cell-epitopes-mhc-class-i-binding-pre-diction-tools-description.
Gonzalez, A. D., Marcela, L., Myrna, C., Lucely, C., Claudia, A. & Eduardo, C. (2005). Epigenetics of Cervical Cancer. An Overview and Therapeutic Perspec-tives. Molecular Cancer, 4(38), 1-24.
Kim, Y., Julia, P., Zhanyang, Z., Dorjee, T., Peng, W. & Jason, G. (2012). Immune Epitope Database Analysis Resource. Nucleic Acids Research, 40, 525-530.
Kurcinski, M., Michal, J., Maciej, B., Andrzej, K. & Sebastian, K. (2015). CABS-Dock Web Server for the Flexible Docking of Peptides to Proteins without Prior Knowledge of the Binding Site. Nucleic Acids Research, 1-6.
Li, B., Xianfang, Z., Chuancui, H. & Yunx-ia, C. (2015). Human papillomavirus Genome-Wide Identification of T-cell Epitopes for Peptide Vaccine Develop-ment Against Cervical Cancer: An Inte-gration of Computational Analysis and Experimental Assay. J Computation Biol, 22(10), 962–974.
Morshed, K., Dorota, P., Marcin, S. & Małgor-zata, P. (2014). Human Papillomavirus (HPV) – Structure, Epidemiology and Pathogenesis. Otolaryngology Polska. Elsevier. pp. 213 – 219
Sompayrac, L. How the Immune System Work. 3ed Edition. (2008). Massachussetts: Well Publishing.
Taupiqurrohman, O. (2016). Desain dan Pengembangan Vaksin Human Papillo-mavirus Tipe 16 Berbasis Epitop Secara In Silico. Thesis. Bandung. Universitas Padjadjaran
Taupiqurrohman, O., Yusuf, M., S. Nuswan-tara, T. & Subroto, T. (2016). Potensi Gen Oncoprotein Human Papillomavi-rus Tipe 16 Sebagai Kandidat Vaksin Kanker Serviks. MKB, 48(35), 84– 91.
Vita, R., Laura, Z., Jason, A. G., Hussein, E., Ilka, H., Nima & Rohini D. (2010). The immune Epitope Database 2.0. Nucleic Acid Research, 38, 854-862.
WHO. (2019). Human papillomavirus (HPV) and cervical cancer. [Downloaded at Agustus 2019]. https://www.who.int/ news-room/fact-sheets/detail/human-pap-illomavirus-(hpv)-and-cervical-cancer
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright and Attribution:
Copyright of published in Jurnal Biodjati is held by the journal under Creative Commons Attribution (CC-BY-NC-ND) copyright. The journal lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as an tranlation), include in collective works (such as an anrhology), text or data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article and do not modify the article in such a way as to damage the author's honor or reputation.
Permissions:
Authors wishing to include figures, tables, or text passages that have already been published elsewhere and by other authors are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate of one of the authors.
Ethical matters:
Experiments with animals or involving human patients must have had prior approval from the appropriate ethics committee. A statement to this effect should be provided within the text at the appropriate place. Experiments involving plants or microorganisms taken from countries other than the authors own must have had the correct authorization for this exportation.
